BLND Blend Labs, Inc. Insider Trading

Haveli Investments buys 1,043,628 shares in 3 transactions at blended avg $1.48; stock now $1.56, -65.3% from 52-week high.

Haveli Investments, LP executed 3 separate purchases totaling 1,043,628 shares for $1,540,214.88 between May 22–27, 2026, at a blended average price of $1.48, lifting holdings to 16,149,188 shares. The current price of $1.56 sits -65.3% from the 52-week high of $4.49, and the stock has gained +10.6% over the past 30 days despite a -10.3% 90-day decline. Across the insider's 5 prior purchases at BLND (May 12–18), all posted positive 90-day returns, ranging from +4.0% to +15.4%, establishing a consistent pattern of well-timed entries at this ticker. However, the company remains unprofitable (net income $-8,049,000.00 in the latest quarter) with annual revenue declining -23.7%, creating a tension between the insider's demonstrated trading accuracy at this stock and the deteriorating business fundamentals that may explain the steep discount relative to recent highs.

Director Haveli Investments bought 777.2K shares at $1.49 avg across 3 trades, raising stake to 15.11M shares (+5.4%); stock down -66.2% from 52-week high.

Haveli Investments, a director, purchased 777,178 shares totaling $1,158,139.78 across three separate transactions on May 19–21, 2026, at prices of $1.49–$1.50 per share. This increased the filer's total holdings from 14,328,382 shares to 15,105,560 shares. The stock is currently trading at $1.52, which represents a -66.2% decline from its 52-week high of $4.49, and has fallen -10.6% over the past 90 days. At the company level, BLND reported a latest-quarter revenue of $30,843,000.00 and net income of $-8,049,000.00, with annual revenue declining -23.7% year-over-year; the company remains unprofitable. Notably, the filer's five prior purchases at this ticker (all in early May 2026) showed strong forward returns, with 90-day outcomes of +4.0%, +5.6%, +15.4%, +6.3%, and +8.2% across those buys.

Haveli Investments LP accumulated 1,527,874 shares of BLND at $1.37 blended average across 3 purchases; prior 5 BLND trades all underwater at 90-day mark.

Haveli Investments, LP (Director) executed 3 separate purchases totaling 1,527,874 shares for $2,090,273.60 between May 14–18, 2026, at prices ranging from $1.33 to $1.47. The director's prior 5 purchases at BLND all generated negative 90-day returns (ranging from -44.2% to -47.1%), with zero instances of well-timed entry at the 90-day measurement. The company is unprofitable (net income $-8,049,000.00 in latest quarter) and has contracted -23.7% in annual revenue, providing limited fundamental support for accumulation. Current price is $1.58, representing -64.8% decline from the 52-week high of $4.49, and these latest purchases at $1.37 already appear underwater relative to near-term price action (52-week range $1.18–$4.49), mirroring the outcome pattern of the director's 5 preceding BLND acquisitions.

Haveli Investments, 10% owner, acquires nearly 2M shares at depressed prices amid company's revenue decline and losses.

Haveli Investments, a 10% beneficial owner and director of Blend Labs, purchased nearly two million shares across three consecutive days in May, expanding its indirect holdings by approximately 18% to over twelve million shares. The purchases occurred while the stock trades well below its 52-week high and near its 52-week low, suggesting the institutional holder is buying into substantial weakness. The company's financials show declining revenue and persistent losses, creating a backdrop of operational pressure that makes large-scale open-market accumulation a notable move by a major shareholder. This is the eighth open-market purchase by Haveli at Blend in the 36-month window—part of a sustained buying pattern—yet prior purchases at this ticker have uniformly declined in value afterward, with all five previous trades showing losses both in the short and long term, raising questions about the timing and thesis behind this continued accumulation.